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Type 2 diabetes mellitus (T2DM) arises primarily due to lifestyle factors and genetics. A number of
lifestyle factors are known to be important in the development of T2DM, including obesity. JTT-553, a
novel Acyl CoA:diacylglycerol acyltransferase 1 inhibitor, reduced body weight depending on dietary fat
in diet-induced obesity (DIO) rats in our previous study. Here, the effect of JTT-553 on glucose meta-
bolism was evaluated using body weight reduction in T2DM mice.
JTT-553 was repeatedly administered to DIO and KK-Ay mice. JTT-553 reduced body weight gain and
fat weight in both mouse models. In DIO mice, JTT-553 decreased insulin, non-esteriﬁed fatty acid
(NEFA), total cholesterol (TC), and liver triglyceride (TG) plasma concentrations in non-fasting conditions.
JTT-553 also improved insulin-dependent glucose uptake in adipose tissues and glucose intolerance in
DIO mice. In KK-Ay mice, JTT-553 decreased glucose, NEFA, TC and liver TG plasma concentrations in non-
fasting conditions. JTT-553 also decreased glucose, insulin, and TC plasma concentrations in fasting
conditions. In addition, JTT-553 decreased TNF-a mRNA levels and increased GLUT4 mRNA levels in
adipose tissues in KK-Ay mice.
These results suggest that JTT-553 improves insulin resistance in adipose tissues and systemic glucose
metabolism through reductions in body weight.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. on behalf of Japanese
Pharmacological Society. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Type 2 diabetes mellitus (T2DM) is characterized by hypergly-
cemia via insulin resistance and relative impairment in insulin
secretion. T2DM is a common disorder and prevalence rises
markedly with increasing degrees of obesity (1). The prevalence of
T2DM has risen in the past decade (2) in large part due to trends in
obesity and lifestyle changes (3).
Obesity causes peripheral resistance to insulin-mediated
glucose uptake (4e6) and may also decrease the sensitivity of
beta-cells to glucose (6). These defects are largely reversed by: þ81 72 681 9783.
imoto).
rmacological Society.
Production and hosting by Elsevie
ons.org/licenses/by-nc-nd/4.0/).weight loss, leading to a decrease in blood glucose levels toward
normal. Obesity is deﬁned as a condition of excessive accumulation
of fat tissue. A combination of excessive energy intake and a lack of
physical activity are thought to explain most cases of obesity (7).
The excessive accumulation of triglycerides (TG) in adipose tissues
results in obesity and is associated with organ dysfunction in
nonadipose tissues. For example, excessive TG deposition in skel-
etal muscle and the liver is associated with insulin resistance (8).
The glycerol phosphate (9) and monoacylglycerol pathway
(10e12) are two major pathways for TG biosynthesis. In the ﬁnal
reaction for both pathways, a fatty acyl-CoA and diacylglycerol
molecule are covalently joined to form TG. This reaction is cata-
lyzed by Acyl CoA:diacylglycerol acyltransferase (DGAT) enzymes.
The genes encoding the two DGAT enzymes, DGAT1 and DGAT2,
have been identiﬁed (13). DGAT enzymes are found in numerousr B.V. on behalf of Japanese Pharmacological Society. This is an open access article
Table 1
Composition of experimental diets.
Macronutrients Source 3.1% fat diet 35% fat diet
% (w/w)
Fat Lard 3.1 35.0
Carbohydrates Starch 39.2 7.3
Sucrose 28.8 28.8
Protein Casein 14.4 14.4
(kcal/g)
Calories 3.291 5.043
D. Tomimoto et al. / Journal of Pharmacological Sciences 129 (2015) 51e5852organs. In particular, DGAT1 is highly expressed in the small in-
testine and fat tissues (14), while DGAT2 is highly expressed in the
liver and fat tissues (15).
Humans with DGAT1 deﬁciencies have not been identiﬁed.
However, several common sequence polymorphisms are present in
the 50 noncoding sequences of the DGAT1 gene. One of these
polymorphisms, C79T, affects promoter activity and has been
associated with alterations in body mass index, diastolic blood
pressure, and high-density lipoprotein (HDL) cholesterol levels in
Turkish women (16).
In DGAT1-transgenic mice that highly express DGAT1, specif-
ically in fat tissues, the accumulation of TG in fat tissues along with
marked increases in body weight were observed when animals
were on a high-fat diet (17). Conversely, DGAT1 knockout mice
showed resistance to the obesogenic effects of a high-fat diet (18).
DGAT1 knockout mice fed a high-fat diet maintained body weights
comparable to mice fed a regular diet. TG levels in the liver and
skeletal muscles were lower and increased energy expenditure was
observed in DGAT1 knockout mice compared with wild type mice.
DGAT1 knockout mice demonstrated increased insulin and leptin
sensitivity compared with wild-type littermates. Therefore, the
phenotypes for DGAT1 gene polymorphisms in humans and DGAT1
deﬁciencies in mice have generated considerable interest for
DGAT1 inhibitors as a potential therapy for obesity and T2DM. We
previously reported the discovery of a new DGAT1 inhibitor, JTT-
553 ([trans-50-(4-Amino-7,7-dimethyl-2-triﬂuoromethyl-7H-pyr-
imido[4,5-b][1,4]oxazin-6-yl)-20,30-dihydrospiro(cyclohexane-1,10-
inden)-4-yl]acetic acid monobenzenesulfonate), using human
DGAT1 inhibiting activity (19,20).
In contrast, several DGAT2 variants were identiﬁed in a similar
population of obese adolescents (21). However, no association be-
tween these polymorphisms and obesity phenotypes was found in
caseecontrol and family-based association studies involving
several hundred subjects.
DGAT2 knockout mice survive for only a few hours after birth
(22), but the knockdown of DGAT2 mRNA levels in the liver with
speciﬁc antisense oligonucleotide (ASO) protected against hepatic
steatosis and lipotoxic alterations in insulin sensitivity (23). DGAT2
ASO treatment also protected against hepatic steatosis in mice
chronically fed a methionine/choline-deﬁcient diet (21).
Therefore, the anti-obesity effects of DGAT1 deﬁciency in mice
have generated considerable interest in DGAT1 inhibition as a po-
tential therapy for obesity.
In a previous report, we evaluated the pharmacological char-
acterization and anti-obesity effects of JTT-553 (24). Because JTT-
553 suppressed fat absorption in the small intestine, fat synthesis
in adipose tissues, and food intake, JTT-553 reduced body weight
and the weight of adipose tissues in DIO rats. In this study, we
evaluated the anti-diabetic effects of JTT-553 using diet-induced
obesity (DIO) models and genetic T2DM models because the
pathogenesis of T2DM can arise through the inﬂuence of genetic or
environmental factors (25).
2. Materials and methods
2.1. Chemicals and reagents
JTT-553 was synthesized in Central Pharmaceutical Research
Institute, Japan Tobacco Inc. (Osaka, Japan). All other reagents used
in this study were obtained commercially.
2.2. Animals and diets
Male B6D2F1 mice were purchased from Charles River Labora-
tories Japan (Yokohama, Japan). Male KK-Ay mice and male C57BL/6j mice were purchased from CLEA Japan (Tokyo, Japan). The ani-
mals were given free access to water and experimental diets
(Table 1). The diets containing 3.1 and 35% (w/w) fat were pur-
chased from Oriental Yeast Co. (Osaka, Japan). The animals were
housed under speciﬁc pathogen-free conditions in a room
controlled for temperature at 23 ± 3 C and humidity of 55 ± 15% in
12-h light/dark cycles (lights on from 8:00 AM to 8:00 PM). All
procedures were conducted according to Japan Tobacco Animal
Care Committee's guidelines.
2.3. Anti-diabetic study in the DIO model
B6D2F1 mice were given a 3.1% or 35% fat diet ad libitum for 6
weeks in order to establish conditions of obesity and insulin
resistance. The animals were used at the age of 10 weeks. In the
previous study, maximal effect of JTT-553 on body weight was
observed at 3 mg/kg/day (24). Therefore, JTT-553 was administered
as a food admixture at a dose equivalent to 3mg/kg/day for 31 days.
Body weight and food consumptionweremeasured on Day 7, 14, 21
and 27 of administration. Blood samples were collected, and
glucose, NEFA, TG, TC and insulin plasma levels were measured on
Day 24. Mice were fasted for 24 h from Day 27 and an intraperi-
toneal glucose tolerance test (1 g/kg) was performed on Day 28. On
Day 31, mice were sacriﬁced by exsanguination under isoﬂurane
anesthesia and the weights of livers and adipose tissues were
measured. TG was extracted from the liver using chloroform-
methanol (2:1) to determine hepatic TG content.
2.4. Glucose uptake in adipose tissues
C57BL/6j mice were given a 3.1% or 35% fat diet ad libitum for 5
weeks in order to establish conditions of obesity and insulin
resistance. In the preliminary study, C57BL/6j mice was superior to
B6D2F1 mice in reducing adipose tissues weight using JTT-553,
C57BL/6j mice were used to evaluate the glucose uptake and in-
sulin sensitivity in adipose tissues. The animals were used at the
age of 10 weeks. In the previous study, maximal effect of JTT-553
on body weight was observed at 3 mg/kg/day, but maximal ef-
fect of JTT-553 on TG synthesis in adipose tissues was observed at
10 mg/kg/day (24). And, obvious signs of toxicity in rats treated
JTT-553 was not observed in the preliminary toxicology study for 4
weeks. Therefore, JTT-553 was administered as a food admixture
at a dose equivalent to 10 mg/kg/day for 39 days. On Day 39, mice
were sacriﬁced by exsanguination under isoﬂurane anesthesia,
and adipose tissues (epididymal and mesenteric fat) were
collected. Tissue fragment samples (approximately 50 mg) from
the same animal were incubated in KrebseRinger phosphate
(KRP) buffer containing 1% BSA and insulin (0 or 1 nM) at 37 C for
30 min. Subsequently, each tissue fragment sample was trans-
ferred to KRP buffer containing 1% BSA, insulin (0 or 1 nM) and
6.67 mCi/mL 2-deoxy-D-[1-3H] glucose, and incubated at 37 C for
5 min. Tissue fragment samples were retrieved and washed with
PBS(e) twice. After the wash, tissue fragment samples were
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Fig. 1. Effects of repeated administration of JTT-553 in DIO mice. JTT-553 was
administered at a dose of 3 mg/kg/day to B6D2F1 mice fed a 35% fat diet for 4 weeks.
The changes in body weight (A) and body weight gain (B) and cumulative food con-
sumption (C) are shown. Data represent mean values ± s.d. (n ¼ 8/group). *p < 0.05,
**p < 0.01 vs. 35% control (Student's t test), ##p < 0.01 vs. 3.1% control (Student's t-
test), !!p < 0.01 vs. 3.1% control (Welch's t test).
D. Tomimoto et al. / Journal of Pharmacological Sciences 129 (2015) 51e58 53shaken with zirconia balls (YTZ® Ball, Nikkato Corporation) in
250 mL of 0.5% SDS aqueous solution to crush the adipose tissue.
The tissue solution was then centrifuged at 10,000 g for 5 min at
room temperature, and 100 mL of the lower water-soluble fraction
was collected and radioactivity measured using a liquid scintilla-
tion counter.
2.5. Anti-diabetic study in the genetic T2DM model
KK-Ay mice were given a 3.1% or 35% fat diet ad libitum for a
week. The animals were used at the age of 5 weeks. JTT-553 was
administered as a food admixture at a dose equivalent to 3 mg/kg/
day for 35 days. Bodyweight and food consumptionweremeasured
on Day 7, 14, 21, 28 and 35 of administration. Blood samples were
collected, and glucose, NEFA, TG, TC and insulin plasma levels were
measured on Day 14. Mice were fasted for 24 h from Day 31 and
blood samples were collected and plasma biochemical parameters
were measured on Day 32. On Day 35, mice were sacriﬁced by
exsanguination under isoﬂurane anesthesia and the weights of
livers and adipose tissues were measured. Hepatic TG content was
measured as described above. GLUT4 and TNF-a mRNA expression
levels in adipose tissues were measured using real-time quantita-
tive polymerase chain reaction (PCR). Total RNAwas extracted from
the adipose tissues with the Rneasy Lipid Tissue Mini Kit (QIAGEN,
Tokyo, Japan). RNAwas transcribed into cDNA usingM-MLV reverse
transcriptase and random primers (Invitrogen, Carlsbad, CA, USA).
The reactionmixturewas incubated for 10min at 25 C,1 h at 37 C,
and 5min at 95 C. Real-time PCR quantiﬁcationwas performed in a
50 mL reaction mixture with an automated sequence detector
combined with ABI Prism 7700 Sequence Detection System soft-
ware (Applied Biosystems, Foster City, CA, USA). The reaction
mixture contained 50 ng of synthesized cDNA, 3.5 mmol/L MgCl2,
0.3 mmol/L primers, 0.1 mmol/L probes, and 0.025 units of Ampli Taq
Gold®. The cycle parameters included 10 min at 95 C followed by
40 cycles of 15 s at 95 C and 60 s at 60 C. The following primers
and FAM-conjugated probes were designed using Primer Express
software (Applied Biosystems): GLUT4 (forward, TGCCCGAAA-
GAGTCTAAAGCG; reverse, CTCTCCAACTTCCGTTTCTCATC; probe,
TGATGTGTCTGACGCACTAGCTGAGCTGA), TNF-a (forward,
AGACCCTCACACTCAGATCATCTTC; reverse, ACTTGGTGGTTTGCTAC-
GACG; probe, CAAAATTCGAGTGACAAGCCTGTAGCCC), and 18s
rRNA (purchased from Applied Biosystems).
2.6. Statistical analysis
Statistical analysis was performed using SAS version 8.2 (SAS
Institute Inc., CA, USA). Data are expressed as mean values ± s.d. An
F test was performed to test homoscedasticity in a single compar-
ison. If homoscedasticity was conﬁrmed, Student's t-test was per-
formed; if not,Welch's t test was used. Differences were considered
signiﬁcant when p < 0.05 (2-sided).
3. Results
3.1. Anti-diabetic effect of JTT-553 in the DIO model
3.1.1. Effect on diet-induced obesity and related parameters
To evaluate the anti-diabetic effect of JTT-553 in the DIO and
insulin resistance model, JTT-553 was orally administered as a food
admixture to mice fed a 35% fat diet for 31 days. Body weight, body
weight gain, and cumulative food consumption in mice fed a 35%
fat diet increased compared with mice fed a 3.1% fat diet. JTT-553
signiﬁcantly decreased body weight gain and cumulative food
intake in mice fed a 35% fat diet during the administration period
(Fig. 1AeC). In the control group fed a 35% fat diet, the weight of
Table 2
Effect of JTT-553 on plasma biochemical parameters in DIO mice.
3.1% fat diet 35% fat diet
Control Control JTT-553
Glucose (mg/dL) 225 ± 11 223 ± 22 219 ± 19
NEFA (mEq/L) 416 ± 103 608 ± 120## 410 ± 46$$
Triglycerides (mg/dL) 102 ± 41 234 ± 117! 160 ± 35
Total cholesterol (mg/dL) 109 ± 7 171 ± 23!! 147 ± 12*
Insulin (ng/mL) 0.85 ± 0.28 19.78 ± 15.24## 5.48 ± 4.98$
Data represent mean values ± s.d. (n ¼ 8), *; p < 0.05 vs. 35% control (Student's t
test), $; p < 0.05, $$; p < 0.01 vs. 35% control (Welch's t test), ##; p < 0.01 vs. 3.1%
control (Student's t-test), !; p < 0.05, !!; p < 0.01 vs. 3.1% control (Welch's t test).
D. Tomimoto et al. / Journal of Pharmacological Sciences 129 (2015) 51e5854adipose tissues increased in association with an elevation in body
weight compared with those in the control group fed a 3.1% fat diet.
JTT-553 administration also resulted in a decrease in the weight of
mesenteric fat as abdominal visceral fat. Liver weight in the control
group fed a 35% fat diet did not increase compared with that in the
control group fed a 3.1% fat diet, and liver weight in the JTT-553
group was comparable to that in the control group (Fig. 2A). In
contrast, TG content in the liver in the 35% fat diet fed control group
was signiﬁcantly elevated compared with that in the 3.1% fat diet
fed control group. JTT-553 had a signiﬁcant lowering effect on TG
content in the liver that had been elevated due to a 35% fat diet
(Fig. 2B).
3.1.2. Effect on blood chemical parameters
An analysis of blood biochemistry values showed that NEFA, TG,
TC and insulin plasma levels in mice fed a 35% fat diet increased
compared with those in mice fed a 3.1% fat diet (Table 2). JTT-553
decreased NEFA, TG, TC and insulin plasma levels. Decreases in
NEFA, TC and insulin plasma levels were signiﬁcant. In the glucose
tolerance test, the plasma glucose level in the 35% control group
was elevated compared with that in the 3.1% control group at
fasting after glucose loading (Fig. 3A). Mice fed a 35% fat diet
exhibited impaired glucose tolerance. Plasma insulin level in the
35% control group was higher than in the 3.1% control group at0.0
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Fig. 2. Effects of repeated administration of JTT-553 in DIO mice. JTT-553 was
administered at a dose of 3 mg/kg/day to B6D2F1 mice fed a 35% fat diet for 4 weeks.
Tissue weight (A) and liver TG content (B) at 4 weeks of JTT-553 treatment are shown.
Data represent mean values ± s.d. (n ¼ 8/group). *p < 0.05, **p < 0.01 vs. 35% control
(Student's t test), ##p < 0.01 vs. 3.1% control (Student's t-test), !!p < 0.01 vs. 3.1%
control (Welch's t test).fasting and after glucose loading (Fig. 3B). Mice fed a 35% fat diet
exhibited insulin resistance. JTT-553 lowered glucose and insulin
plasma levels at fasting and after administration of glucose.
3.1.3. Effect on glucose uptake in adipose tissues
To evaluate the effect of JTT-553 on glucose uptake in adipose
tissues in DIO mice, JTT-553 was orally administered as a food
admixture to C57BL/6j mice fed a 35% fat diet for 39 days.
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teric fat tissues in the 35% fat diet fed group comparedwith the 3.1%
fat diet fed group (Fig. 4A and B). JTT-553 signiﬁcantly increased
glucose uptake in epididymal fat with or without insulin stimula-
tion and JTT-553 signiﬁcantly increased glucose uptake in mesen-
teric fat with insulin stimulation.
3.2. Anti-diabetic effect of JTT-553 in the genetic T2DM model
3.2.1. Effect on diet-induced obesity
To evaluate the anti-diabetic effect of JTT-553 in the genetic
T2DM model, JTT-553 was orally administered as a food admixture
to KK-Ay mice fed a 35% fat diet for 35 days. In mice fed a 35% fat
diet, body weight, body weight gain, and cumulative food con-
sumption increased compared with mice fed a 3.1% fat diet
(Fig. 5AeC). JTT-553 signiﬁcantly decreased body weight, and cu-
mulative food consumption.
3.2.2. Effect on blood chemical parameters
For blood biochemical parameters in a non-fasting state,
glucose, NEFA, TG, and TC plasma levels in mice fed a 35% fat diet
were elevated compared with those in mice fed a 3.1% fat diet
(Table 3). JTT-553 signiﬁcantly decreased glucose, NEFA, and TC0.0
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Fig. 4. Effects of JTT-553 on adipose tissue glucose uptake in DIO mice on Day 39 of
dosing. JTT-553 was administered at a dose of 10 mg/kg/day to C57BL/6j mice fed a 35%
fat diet for 5 weeks. The uptake of 2-deoxyglucose without insulin into epididymal fat
(A) and mesenteric fat (B) are shown. Data represent mean values ± s.d. (n ¼ 6/group).
**p < 0.01 vs. 35% control (Student's t test), #p < 0.05, ##p < 0.01 vs. 3.1% control
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Fig. 5. Effects of repeated administration of JTT-553 in KK-Ay mice. JTT-553 was
administered at a dose of 3 mg/kg/day to KK-Ay mice for 5 weeks. The changes in body
weight (A) and body weight gain (B) and cumulative food consumption (C) are shown.
Data represent mean values ± s.d. (n ¼ 8/3.1% and 35% control groups, n ¼ 7/JTT-553
group). *p < 0.05, **p < 0.01 vs. 35% control (Student's t-test), #p < 0.05, ##p < 0.01 vs.
3.1% control (Student's t-test), !!p < 0.01 vs. 3.1% control (Welch's t test).plasma levels. For blood biochemical parameters in a fasting state,
glucose and insulin plasma levels in mice fed a 35% fat diet were
elevated compared with those in mice fed a 3.1% fat diet (Table 3).
JTT-553 signiﬁcantly decreased glucose, TC, and insulin plasma
levels.
Table 3
Effect of JTT-553 on plasma biochemical parameters in KK-Ay mice on Day 14 of
dosing (non-fasting) and Day 32 of dosing (fasting).
3.1% fat diet 35% fat diet
Control Control JTT-553
Non-fasting
Glucose (mg/dL) 445 ± 82 547 ± 34!! 407 ± 106$$
NEFA (mEq/L) 281 ± 45 684 ± 177!! 501 ± 108*
Triglycerides (mg/dL) 288 ± 92 479 ± 162# 368 ± 149
Total cholesterol (mg/dL) 127 ± 9 167 ± 18## 124 ± 19**
Insulin (ng/mL) 69.62 ± 10.03 42.21 ± 21.87## 36.23 ± 13.66
Fasting
Glucose (mg/dL) 185 ± 29 287 ± 53## 191 ± 41**
NEFA (mEq/L) 371 ± 65 241 ± 23!! 270 ± 77
Triglycerides (mg/dL) 109 ± 30 120 ± 45 100 ± 44
Total cholesterol (mg/dL) 144 ± 12 149 ± 20 105 ± 9**
Insulin (ng/mL) 1.27 ± 0.54 3.77 ± 1.34!! 1.52 ± 0.86**
Data represent mean values ± s.d. (n ¼ 8), *; p < 0.05, **; p < 0.01 vs. 35% control
(Student's t test), $$; p < 0.01 vs. 35% control (Welch's t test), #; p < 0.05, ##;
p < 0.01 vs. 3.1% control (Student's t-test), !!; p < 0.01 vs. 3.1% control (Welch's t
test).
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Fig. 6. Effects of repeated administration of JTT-553 in KK-Ay mice. Tissue weight (A)
and liver TG content (B) at 5 weeks of JTT-553 treatment at a dose of 3 mg/kg/day are
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##p < 0.01 vs. 3.1% control (Student's t-test).
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A 35% fat diet increased theweight ofmesenteric fat and JTT-553
decreased the weight of epididymal and mesenteric fat (Fig. 6A). A
35% fat diet decreased liver weight compared with a 3.1% fat diet;
however, TG content in the liver increased compared with content
in animals fed a 3.1% fat diet (Fig. 6B). JTT-553 signiﬁcantly
decreased liver weight and TG content in the liver. In adipose tissue,
TNF-a mRNA levels increased after feeding with a 35% fat diet and
GLUT-4 mRNA levels decreased after feeding with a 35% fat diet
(Fig. 7A and B). JTT-553 signiﬁcantly decreased TNF-a mRNA levels
and increased GLUT-4 mRNA levels.
4. Discussion
The excessive intake of Western diets is known to increase the
risk of T2DM through the induction of obesity. We previously re-
ported the pharmacological proﬁle of JTT-553, which reduced body
weight gain in DIO rats via suppression of fat absorption in the
small intestine, fat synthesis in adipose tissues, and food intake. In
the present study, we evaluated the anti-diabetic effect of JTT-553
through the improvement of obesity in DIO and genetic T2DM
models, because the pathogenesis of T2DM can arise through the
inﬂuence of genetic or environmental factors.
In DIO mice, plasma insulin levels were elevated and glucose
tolerance was impaired compared with mice fed a 3.1% fat diet.
Plasma NEFA, TG and TC levels also increased in DIOmice. DIOmice
presented with insulin resistance and dyslipidemia. JTT-553
reduced not only plasma lipid levels, but also plasma insulin
levels, and JTT-553 improved glucose tolerance in DIO mice.
Because excessive TG accumulation in adipose tissues and the liver
impaired insulin sensitivity and glucose metabolism in tissues
(8,26), the improvement observed with JTT-553 on glucose toler-
ance in DIO mice was considered to be due to the reduction in fat
weight and liver TG content, and the improvement of insulin
resistance in adipose tissues and the liver. In fact, JTT-553 increased
insulin-dependent glucose uptake in epididymal and mesenteric
fat tissues in DIOmice. It was reported that high fat feeding causes a
marked decrease in the expression of GLUT4 in adipose tissues (27).
It was inferred that the decrease of glucose uptake in adipose tis-
sues in DIO mice in part due to the decrease of GLUT4 expression
and JTT-553 improved the decrease of GLUT4 expression because
JTT-553 did not have acute effect on insulin-dependent glucose
uptake in 3T3-L1 adipocyte. Moreover, JTT-553 did not affect the
adipose cell size evaluated using histological analysis (hematoxylinand eosin staining) in DIOmice (data not shown). Feeding period of
35% fat diet before administration might be long to evaluate the
adipose cell size. It could not conﬁrm morphological alterations in
the adipose tissue in DIO mice, but JTT-553 improved the adipose
tissue functionally. In the previous report, JTT-553 did not affect
food intake and body weight in rats fed a 3.1% fat diet (24). In the
same study, JTT-553 did not affect plasma TG, glucose, and insulin
levels (data not shown). Therefore, it was considered that JTT-553
improved obesity and T2DM derived from high fat feeding in this
study.
In KK-Ay mice fed a 35% fat diet, fed and fasting plasma glucose
levels were elevated compared with mice fed a 3.1% fat diet. Fed
plasma insulin levels in KK-Ay mice fed a 35% fat diet were lower
than in mice fed a 3.1% fat diet. However, fasting plasma insulin
levels in KK-Aymice fed a 35% fat diet were elevated comparedwith
mice fed a 3.1% fat diet. This suggested that insulin resistance had
worsened and insulin secretion from pancreatic beta-cells may be
impaired in KK-Ay mice fed a 35% fat diet. Fed and fasting plasma
glucose levels decreasedwith repeated administration of JTT-553 in
KK-Ay mice fed a 35% fat diet. JTT-553 also reduced fasting plasma
insulin levels. Because JTT-553 decreased adipose tissueweight and
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Fig. 7. Effects of repeated administration of JTT-553 in KK-Ay mice. TNF-alpha (A) and
GLUT4 (B) mRNA expression levels in adipose tissues at 5 weeks of JTT-553 treatment
at a dose of 3 mg/kg/day are shown. Data represent mean values ± s.d. (n ¼ 8/3.1% and
35% control groups, n ¼ 7/JTT-553 group). **p < 0.01 vs. 35% control (Student's t-test),
##p < 0.01 vs. 3.1% control (Student's t-test), !!p < 0.01 vs. 3.1% control (Welch's t test).
D. Tomimoto et al. / Journal of Pharmacological Sciences 129 (2015) 51e58 57liver TG content, the effect of JTT-553 on the improvement of
glucose metabolism was considered to be due to the amelioration
of insulin resistance in adipose tissues and the liver. In adipose
tissues, TNF-a mRNA levels increased after feeding with a 35% fat
diet and GLUT-4mRNA levels decreased after feeding with a 35% fat
diet. Studies in genetically obese animals suggest that the increased
release of TNF-a from adipose tissues may play a major role in the
impairment in insulin activity (28e31) and obese mice genetically
lacking TNF-a have more normal insulin sensitivity (28). In another
study, weight reduction in obese animals was associated with both
improved insulin activity and decreased TNF-a gene expression
(31). GLUT4 is the insulin-regulated glucose transporter. Insulin
induces a rapid increase in the uptake of glucose by inducing the
translocation of GLUT4 from intracellular vesicles to the plasma
membrane (32). According to previous reports, it is possible that
the incremental change in TNF-a expression in adipose tissues in
KK-Ay mice fed a 35% fat diet impaired insulin activity via
decreasing GLUT4 expression. Thus, the weight reduction observed
with JTT-553 was considered to be associated with both decreased
TNF-a mRNA expression and increased GLUT4 mRNA expression,
and the effects on adipose tissues considered to ameliorate insulin
sensitivity in adipose tissues and the entire body.In summary, the present ﬁndings demonstrate that JTT-553
improves glucose metabolism based on weight reductions in both
DIO and genetic T2DM models. These results suggest that JTT-553
may be an effective therapeutic agent for the treatment of T2DM.Conﬂict of interest
None declared.
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